Abbott/Thoratec Corp. is recalling HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS) due to an issue called Extrinsic Outflow Graft Obstruction, (EOGO)
Evidence-based guidelines were created to assist clinicians in the optimal surgical management of thyroid disease.
Xenios has announced that its i-cor Synchronized Cardiac Assist System has received CE marking and can now be sold in...
Containing relevant Learning Zones, guidelines, trials and news.
Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.
Abbott announced it has received FDA approval for its Full MagLev HeartMate 3 Left Ventricular Assist System (also known as...
Mechanical circulatory support improves survival and quality of life in selected patients with advanced heart failure.
Abbott is communicating to physicians about a field corrective action related to the HeartMate 3 Left Ventricular Assist Device (LVAD)....
Honda Motor Co., Ltd. announced that the Honda Walking Assist Device, an assistive device for use in the training and...
Thoratec Corporation announced results from the HeartMate 3 CE Mark trial in patients with heart failure. HeartMate 3 Left Ventricle...